A Phase II Study of AZD4877 (a Novel Anti-mitotic Agent) in Advanced Bladder Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

May 31, 2008

Primary Completion Date

May 31, 2009

Study Completion Date

December 31, 2009

Conditions
Bladder CancerTransitional Cell Bladder CancerUrethra CancerUreter CancerRenal Pelvis Cancer
Interventions
DRUG

AZD4877

Intravenous (IV)25mg/weekly

Trial Locations (36)

Unknown

Research Site, Palo Alto

Research Site, San Bernardino

Research Site, Southington

Research Site, Miami

Research Site, Atlanta

Research Site, Marietta

Research Site, Chicago

Research Site, Scarborough

Research Site, Ann Arbor

Research Site, Minneapolis

Research Site, Hackensack

Research Site, Morristown

Research Site, New York

Research Site, Charlotte

Research Site, Philadelphia

Research Site, Woonsocket

Research Site, Seattle

Research Site, Morgantown

Research Site, Vancouver

Research Site, Halifax

Research Site, Toronto

Research Site, Montreal

Research Site, Québec

Research Site, Berlin

Research Site, Dresden

Research Site, Düsseldorf

Research Site, München

Research Site, Münster

Research Site, Barcelona

Research Site, Madrid

Research Site, Leeds

Research Site, Glasgow

Research Site, London

Research Site, Manchester

Research Site, Southampton

Research Site, Surrey

Sponsors

Lead Sponsor

All Listed Sponsors
lead

AstraZeneca

INDUSTRY